In a recent SEC filing, Black Diamond Therapeutics, Inc. submitted a Form 144 indicating the intention to sell restricted shares. This filing is significant as it provides insight into the company’s plans for potential future fundraising or liquidity needs. Form 144 is typically filed by company insiders or affiliates who plan to sell shares, and it is required to be filed with the SEC when the amount to be sold exceeds 5,000 shares or $50,000 in any three-month period.
Black Diamond Therapeutics, Inc. is a biotechnology company focused on developing precision oncology medicines for patients with genetically defined cancers. Their innovative approach targets allosteric mutant oncogenes for the treatment of solid tumors. To learn more about Black Diamond Therapeutics, visit their website at https://www.blackdiamondtherapeutics.com/.
Form 144 is a notice of proposed sale of securities filed with the SEC by an affiliate of a company. It is used when the affiliate intends to sell restricted, unregistered securities in the open market or through a private sale. This form helps ensure compliance with securities regulations and provides transparency to investors regarding potential insider selling activities.
Read More:
Black Diamond Therapeutics, Inc. Files Form 144 with the SEC
Leave a Reply